Estrogen-mediated immune regulation in human and experimental inflammatory bowel disease
人类和实验性炎症性肠病中雌激素介导的免疫调节
基本信息
- 批准号:10355534
- 负责人:
- 金额:$ 45.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptive TransferAntigensAreaBackBiological AssayBiological Response ModifiersBiopsyCD4 Positive T LymphocytesCandidate Disease GeneCell physiologyCellsChronicCo-ImmunoprecipitationsColitisComplexCrohn&aposs diseaseDataDefectDiseaseEnvironmentEnvironmental Risk FactorEquilibriumEstradiolEstrogen Receptor alphaEstrogen Receptor betaEstrogensEventExhibitsFOXP3 geneFemaleFrequenciesGene Expression RegulationGeneticGenetic TranscriptionGoalsGonadal Steroid HormonesHomeostasisHumanIleitisImmuneImmune ToleranceImmune responseImmunoprecipitationImmunosuppressionImpairmentInflammationInflammatoryInflammatory Bowel DiseasesIntestinal MucosaIntestinesKnockout MiceKnowledgeLeadMediatingMembraneModelingMolecularMusNuclear ReceptorsPathogenesisPathway interactionsPatientsPeripheralPhenotypePublishingRegulatory T-LymphocyteResistanceRoleSamplingSequence HomologySignal TransductionT cell differentiationT cell responseT-LymphocyteTechnologyTestingTissuesTransfectionTransforming Growth Factor betaUlcerative ColitisWorkchromatin immunoprecipitationchronic inflammatory diseaseexperimental studygut inflammationimmunoregulationimprovedin vivoin vivo evaluationinsightloss of functionmicrobialmurine colitisnovelnovel strategiespreventreceptorresponsesextranscriptional reprogrammingtranscriptome sequencing
项目摘要
Project Summary/Abstract
Regulatory T cell (Treg) immunosuppression is critical for maintaining immune tolerance to a diverse array of
potential antigens in the intestinal mucosa. In patients with inflammatory bowel disease (IBD), chronic intestinal
inflammation overwhelms local Treg function, allowing inflammation to persist. Our previous work and that of
others have identified important roles for 17β-estradiol (estrogen, E2) signaling in promoting Treg differentiation
and function. E2 signals through two nuclear receptors, alpha and beta (ERα, ERβ), to modulate gene
transcription in target cells. Although they share high sequence homology, ERα and ERβ mediate distinct and
often opposing functions on gene regulation. In previously published work, we showed that shifting the balance
of E2 signaling towards ERα is generally pro-inflammatory, whereas shifting towards ERβ is generally protective.
In recent preliminary studies using IBD patient samples, we observed significantly diminished ERβ expression
in intestinal biopsy tissues and peripheral T cells from females with active Crohn’s disease (CD). We also found
that ERβ-deficient T cells are resistant to ex vivo, TGFβ-dependent Treg differentiation, and that deletion of ERβ
in a spontaneous ileitis model (SAMP/YitFC, “SAMP” mice) results in significant impairment of Treg
transcriptional and functional responses, contributing to exacerbated inflammation. Therefore, the goal of this
project is to determine the molecular and cellular mechanism(s) by which altered E2 signaling impacts
Treg differentiation and function, contributing to intestinal inflammation. The mechanisms by which E2
signaling cross-talks with inflammatory signals to influence immune cell function are poorly understood. This
proposal seeks to address this knowledge gap through our central hypothesis that dysregulated E2 signaling
contributes to Treg transcriptional remodeling and loss-of-function, facilitating sustained intestinal
inflammation in IBD. In Aim 1, we propose to delineate the molecular mechanisms by which ERα- and ERβ
cross-talk with signaling downstream of TGFβ in primary T cells, influencing TGFβ-dependent Foxp3 expression
and function. Aim 2 will determine the functional impact of rebalancing Treg-specific E2 signaling on intestinal
inflammation in vivo, testing our hypothesis that augmenting Treg-specific ERβ signaling may prevent and/or
rescue intestinal inflammation. Experiments will include adoptive transfer of ERβ-expressing Tregs to SAMP
mice, as well as in vivo assays using a T cell-dependent colitis model. In Aim 3, we plan to determine the
transcriptional and functional effects of rebalancing E2 signaling in CD patient Tregs using novel MaxCyte
transfection technology, assessing ERα- and ERβ-specific effects on (i) TGFβ-dependent Foxp3 induction in
naïve T cells and (ii) ex vivo suppressive function of Tregs. Successful completion of our proposed Aims
will provide key mechanistic insight into the functional impact of E2 signaling in Tregs, an under-studied
area with broad applicability to numerous diseases exhibiting dysregulation of ER expression and/or
activation and subsequent reductions in Treg function.
项目摘要/摘要
调节性T细胞(Treg)免疫抑制对于维持对不同种类的
肠粘膜中的潜在抗原。炎症性肠病(IBD)、慢性肠病
炎症压倒了局部Treg功能,使炎症持续存在。我们以前的工作和
另一些研究发现17β-雌二醇(雌激素,E_2)信号在促进Treg分化中起重要作用
和功能。E2信号通过两个核受体,α和β(ERα,ERβ)来调节基因
靶细胞中的转录。尽管ERα和ERβ具有很高的序列同源性,但它们介导不同的
经常在基因调控上起相反的作用。在之前发表的研究中,我们证明了平衡的转移
向ERα传递的E2信号通常是促炎的,而向ERβ转变通常是保护性的。
在最近对炎症性肠病患者样本的初步研究中,我们观察到ERβ的表达显著降低
在活动性克罗恩病(CD)女性的肠道活检组织和外周T细胞中。我们还发现
ERβ缺陷T细胞对体外转化生长因子β依赖的Treg分化和ERβ缺失具有抵抗力
在自发性回肠炎模型(SAMP/YitFC,“SAMP”小鼠)中,Treg显著受损
转录和功能反应,加剧炎症。因此,这一目标是
项目是确定改变的E2信号影响的分子和细胞机制(S)
Treg的分化和功能,有助于肠道炎症。雌二醇组的作用机制
信号与炎症信号的相互作用影响免疫细胞功能的机制还知之甚少。这
一项提案试图通过我们的中心假设来解决这一知识差距,即调控失调的E2信号
有助于Treg转录重塑和功能丧失,促进持续的肠道
炎症性肠病。在目标1中,我们建议描述ERα-和ERβ的分子机制
与原代T细胞转化生长因子β下游信号的相互作用,影响转化生长因子β依赖的foxp3的表达
和功能。目标2将确定重新平衡Treg特异性E2信号对肠道的功能影响
体内炎症,验证了我们的假设,即增强Treg特异性ERβ信号可能预防和/或
挽救肠道炎症。实验将包括将表达ERβ的Tregs过继转移到SAMP
小鼠,以及使用T细胞依赖的结肠炎模型的体内试验。在目标3中,我们计划确定
新型MaxCyte在CD患者树突中重新平衡E2信号的转录和功能效应
转染技术,评估ERα和ERβ对(I)转化生长因子β依赖的foxp3诱导的作用
幼稚T细胞和(Ii)Tregs的体外抑制功能。圆满完成我们提出的目标
将为E2信号在Tregs中的功能影响提供关键的机制洞察,一个正在研究中的
对多种表现出ER表达和/或失调的疾病具有广泛适用性的区域
Treg功能的激活和随后的减少。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wendy Ann Goodman其他文献
Wendy Ann Goodman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wendy Ann Goodman', 18)}}的其他基金
Estrogen-mediated immune regulation in human and experimental inflammatory bowel disease
人类和实验性炎症性肠病中雌激素介导的免疫调节
- 批准号:
10853530 - 财政年份:2023
- 资助金额:
$ 45.76万 - 项目类别:
Estrogen-mediated immune regulation in human and experimental inflammatory bowel disease
人类和实验性炎症性肠病中雌激素介导的免疫调节
- 批准号:
10574487 - 财政年份:2021
- 资助金额:
$ 45.76万 - 项目类别:
Estrogen-mediated immune regulation in human and experimental inflammatory bowel disease
人类和实验性炎症性肠病中雌激素介导的免疫调节
- 批准号:
10182035 - 财政年份:2021
- 资助金额:
$ 45.76万 - 项目类别:
Role of regulatory T cell glucocorticoid-induced leucine zipper (GILZ) in the chronically inflamed intestine
调节性 T 细胞糖皮质激素诱导的亮氨酸拉链 (GILZ) 在慢性炎症肠道中的作用
- 批准号:
10215504 - 财政年份:2020
- 资助金额:
$ 45.76万 - 项目类别:
Role of regulatory T cell glucocorticoid-induced leucine zipper (GILZ) in the chronically inflamed intestine
调节性 T 细胞糖皮质激素诱导的亮氨酸拉链 (GILZ) 在慢性炎症肠道中的作用
- 批准号:
10057684 - 财政年份:2020
- 资助金额:
$ 45.76万 - 项目类别:
Molecular mechanisms contributing to gender differences in regulatory T cell function in Crohn's disease and experimental IBD
克罗恩病和实验性 IBD 调节性 T 细胞功能性别差异的分子机制
- 批准号:
9750684 - 财政年份:2015
- 资助金额:
$ 45.76万 - 项目类别:
Molecular mechanisms contributing to gender differences in regulatory T cell function in Crohn's disease and experimental IBD
克罗恩病和实验性 IBD 调节性 T 细胞功能性别差异的分子机制
- 批准号:
9146962 - 财政年份:2015
- 资助金额:
$ 45.76万 - 项目类别:
KLF2 as a Regulator of Metabolic Inflammation
KLF2 作为代谢炎症的调节剂
- 批准号:
8254121 - 财政年份:2012
- 资助金额:
$ 45.76万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 45.76万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 45.76万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 45.76万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 45.76万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 45.76万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 45.76万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 45.76万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 45.76万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 45.76万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 45.76万 - 项目类别: